Opens in a new tab

bioMérieux UK v Labrador Diagnostics (CoA, 17 February 2026)

Date17 February 2026
CourtCoA
DivisionLuxembourg (LU)
Type of actionAppeal RoP220.1
Case number(s)UPC_CoA_937/2025;UPC_CoA_938/2025
Registry referenceUPC-COA-0000937/2025 · UPC-COA-0000938/2025
PartiesbioMérieux UK Limited, bioMérieux Benelux BV, bioMérieux SA, bioMérieux Deutschland GmbH, bioMérieux Portugal, Lda., bioMérieux Italia S.p.…

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

In an order of 17 February 2026 (UPC_CoA_937/2025 and UPC_CoA_938/2025), the judge-rapporteur of the Court of Appeal refused the bioMérieux companies, appealing the Milan Central Division decision of 23 October 2025 maintaining Labrador Diagnostics’ EP 3 756 767 in amended form, both a stay pending EPO opposition proceedings and an extension of the deadline for the statement of grounds of appeal.

Question

Should appeal proceedings be stayed where the EPO Opposition Division is due to decide shortly and has issued a preliminary opinion favouring revocation, and should the deadline for the grounds of appeal be extended to align with a possible infringement appeal?

Decision

As a rule the court does not stay proceedings, and parallel opposition does not in itself justify an exception (paragraphs 13 and 14). Even where an EPO decision is expected rapidly, a stay remains discretionary (paragraphs 16 to 19): the Opposition Division decision will arrive during the appeal and can be relied on then, so a stay would serve no purpose and cause unjustified delay (paragraphs 20 to 23). An extension under Rule 9.3(a) requires exceptional circumstances, absent here: the appellants do not need the opposition outcome to state their grounds, the infringement appeal is merely possible, and hearing the appeals together under Rule 220.5 would achieve alignment (paragraphs 24 to 29).

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Art. 33(10)
Rules of Procedure
Rules 9.3(a), 220.5 and 295(a)
Case law cited
Carrier v Bitzer, Court of Appeal, 28 May 2024, Juul v NJOY, Court of Appeal, 30 April 2025 (UPC_CoA_5/2025), Meril v Edwards, Court of Appeal, 21 November 2024, Bega v Washtower, Court of Appeal, 24 September 2025

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: UPC Court of Appeal.

Dhenne Avocats blog: UPC Appeals: What the Numbers Show.

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

  • UPC_CoA_937/2025 official number
  • UPC_CoA_938/2025 official number

Follow these proceedings

Parties

  • claimantbioMérieux UK Limited, bioMérieux Benelux BV, bioMérieux SA, bioMérieux Deutschland GmbH, bioMérieux Portugal, Lda., bioMérieux Italia S.pFollow this party
Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Appeal RoP220.1
Outcome (Dhenne Avocats summary)
Le juge rapporteur refuse le sursis à statuer dans l'attente de l'opposition devant l'OEB et la prorogation du délai du mémoire d'appel, faute d'utilité et de circonstances exceptionnelles.
Appeal
Decision of the Court of Appeal.
Instance
Court of Appeal decision.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 3 756 767Mentioned in the analysis (role not qualified)
Also mentioned in 5 other decision(s): Labrador Diagnostics v bioMérieux (CFI, 28 January 2026) · bioMérieux UK v Labrador Diagnostics (CFI, 23 October 2025) · Labrador Diagnostics v bioMérieux (CFI, 26 September 2025) · bioMérieux v Labrador Diagnostics (CFI, 18 July 2025) · Labrador Diagnostics v bioMérieux (CFI, 23 April 2025)
not recordednot recordednot recordedEspacenet
links not checked
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.